Background: For decades, tumour hypoxia has been pursued as a cancer treatment target. However, prognostic and predictive biomarkers are essential for the use of this target in the clinic. This study investigates the prognostic value of a hypoxia-induced gene profile in localised soft tissue sarcoma (STS).
About a quarter of patients with primary localised soft tissue sarcoma (STS) die within the first 5 years of being diagnosed (Maretty-Nielsen et al, 2014) . Risk stratification is difficult and adjuvant treatment is toxic and has low efficacy. Novel prognostic and predictive markers are needed to make informed decisions and guide individualised treatment (Hunter et al, 2016) .
Hypoxia is an adverse prognostic factor in different malignancies (Hockel et al, 1996; Evans et al, 2001; Evans and Koch, 2003; Nordsmark et al, 2005; Busk and Horsman, 2013) and its role in sarcoma has recently been explored (Kim et al, 2015) . There is experimental evidence implicating hypoxia in increasing metastatic potential and dissemination of sarcomas Kim et al, 2013; El-Naggar et al, 2015) . Traditionally, the Eppendorf needle electrode has been used for measuring tumour hypoxia. These measurements have shown that the level of pretreatment tumour oxygenation is a prognostic marker for disease-specific survival in STS patients (Nordsmark et al, 2001) , and that preoperative low tumour pO 2 could be an indicator of aggressive disease (Brizel et al, 1996) . However, the Eppendorf method is invasive and requires special equipment and expertise.
An alternative way to determine tumour hypoxia is to monitor the expression of certain hypoxia-induced genes, whose change in expression is important for cellular adaptation to an anaerobic environment. This is a non-invasive and rapid method to reveal the presence of hypoxia in STS viable tumour tissue. If the hypoxiainduce gene profile is of prognostic value, it may help stratify patients for treatment either with more aggressive modalities or with hypoxia-targeting drugs.
The hypoxia-induced gene profile investigated in this paper was developed as a predictive marker for hypoxic modification of radiotherapy in head and neck cancer (Toustrup et al, 2012) and includes genes that are upregulated by hypoxia in a pH-independent manner (Sorensen et al, 2010) .
The aim of the present study was to investigate the prognostic role of this hypoxia-induced gene profile in STS patients.
MATERIALS AND METHODS
Patient cohorts. The study was performed on a test cohort of 55 patients and validated in an independent cohort of 77 patients.
The test cohort was built around the original material of 42 STS patients investigated by Nordsmark et al (2001 and by Bentzen et al (2003) in which hypoxia was measured using Eppendorf method between 1993 and 2001. Four patients were excluded because of benign histology and 8 patients because ofto lack of available tissue samples. The remaining 30 patients were matched 1 : 2 to the Aarhus Sarcoma Registry (ASR), a recently validated comprehensive clinical population-based database (MarettyNielsen et al, 2013) .
The matching was done based on histological type, age at diagnosis, sex, and year of diagnosis. Exact match was not possible, but the cases that were 'best possible matches', according to the above-mentioned order of criteria, were manually selected. Inclusion was restricted to high-grade, localised STS with stored formalin-fixed, paraffin-embedded (FFPE) tissue samples taken before any treatment and with sufficient tissue for high-quality mRNA analysis. This resulted in a test cohort of 55 patients. For inclusion and exclusion criteria, see Figure 1 .
The validation cohort was chosen among all patients treated with curatively intended surgery and postoperative radiation therapy for localised STS between 1998 and 2008. Patients without pretreatment FFPE tissue samples, as well as tissue samples with insufficient mRNA quality were excluded. This resulted in a cohort of 77 patients. Power calculation for the validation cohort was based on an expected hazard ratio (HR) of 2.0 between the more hypoxic and the less hypoxic patient groups. Based on this calculation, 66 patients were needed to detect this difference with 80% power.
The median follow-up time was 5.5 years (0.2-23.8) and for patients still alive the median follow-up time was 8.2 years (4.4-23.8).
Tissue samples and preparation. FFPE tissue samples taken at the time of biopsy or surgery were used for investigation of the hypoxia-induced genes. These tissue samples represented different histological types: undifferentiated pleomorphic sarcoma (UPS; n ¼ 51), liposarcoma (n ¼ 28), leiomyosarcoma (n ¼ 16), synovial sarcoma (n ¼ 14), malignant peripheral nerve sheath tumour (n ¼ 8), fibrosarcoma (n ¼ 7), extra osseous osteosarcoma (n ¼ 3), rhabdomyosarcoma (n ¼ 3), and extra-osseous Ewing/PNET (n ¼ 2). Information about time from tissue collection to fixation and fixation times was not available. Samples were excluded if haematoxylin and eosin (HE) staining showed either 490% necrotic or 100% normal tissue. A specialised sarcoma pathologist reviewed all HE staining for estimation of the degree of necrosis.
Total RNA was extracted from 7-mm whole FFPE tissue sections by the Tissue Preparation System with VERSANT Tissue Preparation Reagents (Siemens Healthcare Diagnostics, Tarrytown, NY, USA), a fully automated, bead-based RNA isolation method as described elsewhere (Bohmann et al, 2009) . DNase I treatment was applied to remove any potential genomic DNA before cDNA preparation. Purified mRNA from FFPE tissue samples is known to be highly degraded and the mRNA quantity was therefore not determined. Yet, to perform RT-qPCR on the partly degraded RNA, short amplicons and pre-amplification steps were used as described and validated previously (Toustrup et al, 2011; Soes et al, 2013) .
Primers and RT-qRCR. The cDNA preparation was performed using the high-capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. First 10 cycles of pre-amplification were completed with few modification of the manufacturer's protocol (Taqman Preamp Master Mix, Applied Biosystems) as described elsewhere (Soes et al, 2013 3 for one of the reference genes, the entire sample was excluded. DCq-values were generated by normalising the Cq-values using the geometric mean of the reference genes. The tissue samples of the test cohort were sorted according to the median rank of the gene expression levels for the 15 genes included in the profile. The gene expression for each investigated gene was ranked under the assumption that a high expression was caused by hypoxia. Although Toustrup et al (2011) divided the patients into more hypoxic and less hypoxic groups based on the oxygen tension measurement, we have done this division according to the expression of the genes in the test cohort. Individual samples were classified by calculating the distance (D) between the DCq-values obtained in individual samples and the median DCq-values of the test cohort in a manner similar to what was previously described by Toustrup et al (2011) . Allocation into a more or a less hypoxic group was determined by the highest B/W ratio in the test cohort. The B/W ratio is defined as the variation between groups divided by the variation within a group. The cutpoints for the individual genes obtained in the test cohort were applied to the validation cohort to allocate patients into the more or the less hypoxic group, independent of the patient outcome. The primary end point was disease-specific mortality, timed from the date of sarcoma diagnosis until death with sarcoma as death from other causes was regarded as a competing event. Secondary end points were as follows: overall mortality, timed from the date of sarcoma diagnosis until death from any cause, and development of metastatic disease, defined as metastasis with no possibility of curative treatment, timed from the date of primary sarcoma diagnosis until diagnosis of metastatic disease. The study ended on 15 April 2013. Patients alive at this date were censored. Differences in patients characteristics were tested using w 2 -test, Fishers exact test, or Wilcoxon rank test. The cumulative incidence function was reported for disease-specific mortality or as overall mortality using the Fine and Gray model. Crude and adjusted estimates were reported with 95% confidence interval (CI) using the Cox proportional hazard model. The assumptions for the individual model were tested and no violations were observed. Adjustments were made for potential confounders affecting the association between the gene expression and the outcome. The confounders included were as follows: age at diagnosis (continuous), primary tumour size (continuous), comorbidity (yes vs no), site (axial/pelvis/head vs extremities), histological type (liposarcoma vs UPS vs synovial sarcoma vs others), and surgical margin (wide vs intralesional/marginal). The choice of potential confounders was based on literature review. In the multivariate analysis, 12 patients with grade 2 tumours, 6 patients with superficial tumours, and 4 patients who received chemotherapy were excluded. The model including the hypoxia-induced gene profile was tested against the model without the profile using likelihood-ratio test. The robustness of the final model including the hypoxia-induced gene profile was tested using the bootstrapping method with 1000 iterations.
Heat maps visualising the gene expression levels were generated by Genesis release 1.7.6 (Sturn et al, 2002) using the median centred data. The correlation between different tissue blocks from the same patient was tested by concordance correlation coefficient (Rho_c). A two-sided P value o0.05 was regarded as significant. All statistical analyses were performed by using Stata version 14 (Metrika Consulting AB, Västervik, Sweden).
Ethics. The Ethics Committee of Denmark (no 1-10-72-233-12) and the Danish Agency of Data Protection (no 2012-41-0657) have approved the study.
RESULTS
Test and validation cohorts. Patient, tumour and treatment characteristics for the test, and validation cohorts are shown in Table 1 . There were statistically significant differences between the test and validation cohorts regarding the number of patients treated with postoperative radiation therapy, tumour grade, tumour depth, and margin after primary surgery.
The robustness of the gene expression in different tissue samples (different pathological blocks) from the same patient were tested in 15 patients. The strong correlation was manifested by a concordance correlation coefficient value of 0.88 (95% CI: 0.85; 0.91). For the concordance of all the genes in the profile and each individual gene see Supplementary Document II (Supplementary Figure IIA and IIC) . In 13 patients, the analysis of both tissue samples (blocks) lead to the same hypoxia classification, whereas in 2 patients, the classification was different between the blocks. For 16 patients, corresponding oxygen tension measurements and expression of the hypoxia-induced gene profile were present. A reverse association between the oxygen tension measurement and the gene expression was found as shown in Table 2 . The Spearman's r coefficient was indicating a weak correlation of À 0.45 (P ¼ 0.04) between pO 2 measurements and tumour size. The larger the tumour, the lower was the oxygen tension measurements (Supplementary Figure IIB) .
Survival analysis. The expression of the genes expressions of the test cohort in the more and the less hypoxic tumours are illustrated in the heat maps (Figure 2A ). Figure 2B shows the disease-specific mortality and Figure 2C the overall mortality in the test cohort for the more and the less hypoxic groups of patients. In the test cohort, the HR for patients with a high expression of the gene profile (the more hypoxic group) was 4.09 (95% CI: 1.34; 12.46), P ¼ 0.013, compared with patients with a low expression of the gene profile regarding disease-specific mortality. The number of patients who experienced recurrent disease was higher in the more hypoxic, compared with the less hypoxic group; odds ratio of 3.96 (95% CI: 0.98; 14.7), P ¼ 0.03.
Seventy-seven patients with localised grade 2 or 3 STS treated with surgical resection and postoperative radiation therapy (but no chemotherapy) were divided into a more hypoxic and a less hypoxic groups. The gene expression values used to set the cut-point of each gene in the test cohort were applied to the validation cohort. Of these 77 patients, 30 (39%) were allocated to the more hypoxic group and 47 (61%) were allocated to the less hypoxic group. Interestingly, all patients with synovial sarcoma were allocated to the less hypoxic group. Figure 2D shows the heat map of the gene expression in the validation cohort. Both the disease-specific mortality ( Figure 2E ) and overall mortality ( Figure 2F ) were significantly higher in patients with more hypoxic tumours in the validation cohort. The HR was 2.03 (95% CI: 1.02; 4.04) P ¼ 0.045 for disease-specific mortality and 2.01 (95% CI: 1.11; 3.64) P ¼ 0.02 for overall mortality. In the validation cohort, 16 out of 30 (53%) of patients in the more hypoxic group developed recurrent/metastatic disease compared with 23 out of 47 (49%) of patients in the less hypoxic group.
Disease-specific mortality and overall mortality in the pooled data. Pooled analysis of the test and validation cohorts after exclusion of grade 2 tumours, superficial tumours, and patients treated with additional chemotherapy were done. The selection was done to eliminate confounding by grade and superficial location, as only a few patients had these characteristics. Patients, tumour, and treatment-related characteristics are shown in Table 3 . The results confirmed the prognostic value of the hypoxia-induced gene profile. Patients with high expression of the gene profile had significantly higher cumulative incidence of death from sarcoma compared with patients with low expression. The model including the hypoxia-induced gene profile was significantly better in a likelihood-ratio test (P ¼ 0.0019) than the model without the hypoxia-induced gene profile. Both univariate and multivariate analyses were performed and are shown in Table 4 . The adjusted HR for the development of metastatic disease was 2.61 (1.27; 5.33) P ¼ 0.009 for patients with more hypoxic tumours compared with the less hypoxic tumours. Using bootstrapping, the HR was 3.18 (95% CI: 1.0; 9.8) P ¼ 0.044.
DISCUSSION
The hypoxia-induced gene profile investigated in this paper was developed in head and neck cancer (Toustrup et al, 2012) , but recent in vitro data have demonstrated a potential in other cancer types . This study demonstrated that the expression of the hypoxia-induced gene profile tested in pretreatment FFPE tissue is a prognostic factor for STS patients. The unique composition of genes presented here takes into account different mechanisms by which hypoxia affects tumour biology and the collective effect of these genes has not been described in sarcomas before. The hypoxia-induced gene profile includes genes such as LOX, P4HA1, and P4HA2 that are involved in extracellular matrix modulation, a mechanism affected by hypoxia. The modulation of the extracellular matrix is important to facilitate tumour cell migration and enhances sarcoma metastasis as shown by Eisinger-Mathason et al (2013). pt_1  pt_2  pt_3  pt_4  pt_5  pt_6  pt_7  pt_8  pt_9  pt_10  pt_11  pt_12  pt_13  pt_14  pt_15  pt_16  pt_17  pt_18  pt_19  pt_20  pt_21  pt_22  pt_23  pt_24  pt_25  pt_26  pt_27  pt_28  pt_29  pt_30  pt_31  pt_32  pt_33  pt_34  pt_35  pt_36  pt_37  pt_38  pt_39  pt_40  pt_41  pt_42  pt_43  pt_44  pt_45  pt_46  pt_47  pt_48  pt_49  pt_50  pt_51  pt_52  pt_53  pt_54  pt_55   pt_1  pt_2  pt_3  pt_4  pt_5  pt_6  pt_7  pt_8  pt_9  pt_10  pt_11  pt_12  pt_13  pt_14  pt_15  pt_16  pt_17  pt_18  pt_19  pt_20  pt_21  pt_22  pt_23  pt_24  pt_25  pt_26  pt_27  pt_28  pt_29  pt_30  pt_31  pt_32  pt_33  pt_34  pt_35  pt_36  pt_37  pt_38  pt_39  pt_40  pt_41  pt_42  pt_43  pt_44  pt_45  pt_46  pt_47  pt_48  pt_49  pt_50  pt_51  pt_52  pt_53  pt_54  pt_55  pt_56  pt_57  pt_58  pt_59  pt_60  pt_61  pt_62  pt_63  pt_64  pt_65  pt_66  pt_67  pt_68  pt_69  pt_70  pt_71  pt_72  pt_73  pt_74  pt_75  pt_76  pt_77   ADM  ALDOA  ANKRD37  BNIP3  BNIP3L  EGLN3  FAM162A  KCTD11  LOX  NDRG1  P4HA1  P4HA2  PDK1  PFKB3  SLC2A1   ADM  ALDOA  ANKRD37  BNIP3  BNIP3L  EGLN3  FAM162A  KCTD11  LOX  NDRG1  P4HA1  P4HA2  PDK1  PFKB3 Our findings showing an upregulation of genes encoding proteins involved in the glycolysis, such as SLC2A1, PFKB3, ALDOA, and PDK1, could be explained by the metabolic switch from oxidative phosphorylation to glycolysis as a result of tumour cell hypoxia (Payen et al, 2015) . However, it is important to remember that these genes could also be upregulated in cancers for reasons unrelated to hypoxia. The prognostic impact of these glycolysis genes are in concordance with the data showing that the total tumour glycolysis estimated by FDG PET/ CT in sarcoma patients is associated with metastatic disease (Choi et al, 2013) .
All the genes included in the profile are involved in the mechanisms that facilitate aggressive tumour behaviour such as metastasis and/or resistance to treatment (Erler et al, 2009; Cairns et al, 2011; Gilkes et al, 2014; Tung et al, 2015) . Therefore, this gene profile may be a generally applicable signature for hypoxic and/or aggressive tumours.
To the best of the authors' knowledge, this is the second largest study of a prognostic gene profile in STS patients after the CINSARC profile (Chibon et al, 2010 ). Yet, because of the various histological subtypes, the number of patients in each histological subtype is still relatively small. This hinders any pathology-specific analysis of data.
The relative wide 95% CIs of the survival estimate means these are subject to some uncertainty. Furthermore, the lower HR for hypoxia in the validation cohort indicates a weaker relationship between DFS and the hypoxic gene signature, and confirms the importance of further validation of this gene signature in an independent cohort. This, however, does not affect the fact that the differences in disease-specific mortality, overall mortality, and development of metastasis were significant. The development of metastasis was the secondary end point used in this study. This end point was defined as metastasis with no possibility of curative treatment. Specifying the palliative intent in the definition of the end point was based on the assumption that tumours that develop solitary or oligometastasis that could be treated curatively may have a different and less aggressive biology compared with tumours that develop widespread systemic disease.
Intra-tumour heterogeneity is a well-known issue in regards to the extent of hypoxia (Horsman et al, 2012) , and this is a concern for biomarker studies based on single tumour biopsies. For the hypoxia signature, this question has been raised in a previous study (Toustrup et al, 2016) , where intra-tumour heterogeneity was tested in multiple biopsies with different tumour tissue content from individual head and neck cancer patients. It was found that for the majority of patients, all biopsies from the same patient were classified the same. The conclusion from this study was, that if multiple biopsies are available, the optimal biopsy is selected by taking the relative content of invasive carcinoma, minimal necrosis, and the total size of the tumour biopsy into account. We have in this study performed a similar validation as described in Material and Methods and most patients were classified in the same groups used two different tissue samples.
A major strength of the present study is that the cut-point (DCq-value) determined by the test cohort for each gene was applied to the validation cohort independent of the patient's outcome. The data shown by Sorensen et al indicated that this hypoxia-induced gene profile may be universal for cancer, whereas our data indicated that different cancers may have different cut-points for each gene as the cut-points found in this study were indeed different from those found by Toustrup et al. This study also suggests that even various histological types of sarcomas may have different cut-points. Other points of strength in this study are as follows: the strong correlation between tissue samples taken from the same patient, who testified for the robustness of the data, and the significant association between disease-specific survival and the hypoxiainduced gene profile, shown by using the bootstrapping method on the pooled data.
Data for this study were collected from a comprehensive newly validated sarcoma database covering all sarcoma patients in a welldefined geographic part of Denmark (Maretty-Nielsen et al, 2013) . In the present study, we adjusted for confounders, which are known to affect overall survival of STS; even so, we observed a highly significant association between the hypoxia-induced gene profile and disease-specific mortality. Another important point is that the proposed analysis using FFPE tissue samples to evaluate the expression level of the hypoxia-induced gene profile can be used in clinical practice.
In the present study, there was no association between the hypoxia-induced gene expression and the Eppendorf oxygen tension measurements in a small group of 16 patients with high-grade sarcoma. This could simply be owing to the small number of patients with data available on tumour oxygen tension status.
Another possible explanation could be that pO 2 measurements with the Eppendorf method could have been affected by, for example, tumour size or the degree of necrosis within a tumour. Previous clinical data in STS showed no such association, neither between tumour pO 2 or tumour necrosis or size, respectively (Nordsmark et al, 1996) . Preclinical studies using mouse models have collectively shown that the larger the tumour, the higher was the degree of necrosis and the lower was the oxygen tension inside the tumour (Vaupel et al, 1989; Khalil et al, 1995; Milross et al, 1997) .
In this study, only a week correlation between tumour size and oxygen tension measurements was observed (Supplementary Figure IIB) . This weak correlation can therefore cast a shadow of doubt on whether these genes in sarcomas are driven by hypoxia directly and not by other hypoxia-independent signalling pathways.
Indeed, our results cannot answer the question of whether these genes in sarcomas are driven by hypoxia or by other signalling pathways that are totally or partly independent of hypoxia. The distinction is important for understanding the underlying mechanism and determining the predictive value of this profile. As the current study was not designed to make this distinction, this point will be investigated in future studies testing the predictive role of this profile in determining the response to anti-hypoxic drugs alone or in combination with chemotherapy.
Determining tumour hypoxia using panel of genes, referred to as Hypoxia Gene Expression Signatures is now a commonly used strategy (Toustrup et al, 2012; Harris et al, 2015; Pettersen et al, 2015) This is due to the advantages of using a cumulated gene response to hypoxia, instead of focusing on a single biomarker. Previously, immunohistochemistry (IHC) using single markers has been used in number of clinical studies, but because of the number of disadvantages of this method (Harris et al, 2015) it was not used Abbreviations: CI ¼ confidence interval; HR ¼ hazard ratio; UPS ¼ undifferentiated pleomorphic sarcoma. Number of events analysing overall mortality was 66. Number of events analysing disease specific mortality was 44. Crude and adjusted analysis of potential prognostic factor for overall and disease-specific mortality for patient with localised high-grade disease and treated with surgery (n ¼ 110). Superficial and grade 2 tumours were excluded. The Bold and italic entries are the significant results.
a Adjustments were made for tumour size, histology, margin, age, site, and comorbidity. The histological types were group into synovial sarcoma vs all other histological types.
here. It was also felt treat the use of IHC would not add more information to the results particularly that the correlation between the expression of the hypoxia inducible genes included in the 15-gene hypoxia-induced gene profile and tumour hypoxia has been validated in a preclinical study, with tumour hypoxia being assessed by FAZA, an exogenous hypoxia marker (Toustrup et al, 2011) .
In conclusion, the results of the present paper suggest a new hypoxia-induce gene profile prognostic for STS patients.
